Previous studies reported enhanced sensitivity to BET inhibitors in hematologic cancer models with high MYC expression due to potent MYC silencing and down-regulation of Myc-driven transcriptional programs [16–18]. Here, MYC is linked to hematopoietic and lymphoid cell neoplasm.